Results 81 to 90 of about 8,546 (246)
Loop diuretics have anxiolytic effects in rat models of conditioned anxiety. [PDF]
PLoS ONE, 2012 A number of antiepileptic medications that modulate GABA(A) mediated synaptic transmission are anxiolytic. The loop diuretics furosemide (Lasix) and bumetanide (Bumex) are thought to have antiepileptic properties.
Andrew D Krystal +2 more
doaj +1 more source
JGH Open, Volume 10, Issue 4, April 2026.ABSTRACT Background Tolvaptan promotes electrolyte‐free water excretion and is widely used in Asia for ascites, but in Western countries its use is limited to hyponatremia because of hepatotoxicity concerns. Methods We performed a retrospective cohort study using the TriNetX Research Network, emulating a target trial of cirrhotic patients with ...
Kazuya Okushin +5 more
wiley +1 more source
Selective effects of bumetanide on chloride transport in bullfrog cornea
, 1978 Frog corneas were mounted in a modified Ussing chamber and short-circuit current (SCC) and unidirectional Cl fluxes were measured. Bumetanide, a loop diuretic, at concentrations as low as 10(-7) M, reduced the SCC 29%.
H. F. Schoen, O. A. Candia
core +1 more source
Frontiers in Molecular Neuroscience, 2017 Fragile X syndrome (FXS) is the most common monogenetic cause of intellectual disability and autism. The disorder is characterized by altered synaptic plasticity in the brain.
Shimriet Zeidler +3 more
doaj +1 more source
Potassium channel and NKCC cotransporter involvement in ocular refractive control mechanisms. [PDF]
PLoS ONE, 2008 Myopia affects well over 30% of adult humans globally. However, the underlying physiological mechanism is little understood. This study tested the hypothesis that ocular growth and refractive compensation to optical defocus can be controlled by ...
Sheila G Crewther +2 more
doaj +1 more source
Alzheimer's disease drug development pipeline: 2026
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 2, April/June 2026.Abstract INTRODUCTION Discovery and development of new therapies for Alzheimer's disease (AD) are urgently needed to address the world's growing population of individuals on the AD pathophysiological continuum. Clinicaltrials.gov is a resource for studying drugs in development for treatment of AD. RESULTS There are currently 158 drugs in 192 AD trials.
Jeffrey L. Cummings +6 more
wiley +1 more source
Dibutyryl cAMP activates bumetanide-sensitive electrolyte transport in Malpighian tubules
, 1991 The effects of dibutyryl adenosine 3',5'-cyclic monophosphate (DBcAMP) and bumetanide (both 10(-4) M) on transepithelial Na+, K+, Cl-, and fluid secretion and on tubule electrophysiology were studied in isolated Malpighian tubules of the yellow fever ...
T. L. Pannabecker +5 more
core +1 more source
Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol
BMC Psychiatry, 2022 Background Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs).
Lisa Geertjens +6 more
doaj +1 more source
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 2, April/June 2026.Abstract BACKGROUND There are currently no US Food and Drug Administration‐approved treatments for vascular dementia (VaD). Genome‐wide approaches have successfully identified druggable targets and treatments for various disorders. In this study, we performed druggable genome‐wide two‐sample Mendelian randomization (2SMR) analysis to identify possible ...
Matthew J. Lennon +4 more
wiley +1 more source
Uptake of bumetanide into isolated rat hepatocytes and primary liver cell cultures
, 1989 Uptake of bumetanide into rat liver cells was investigated using isolated hepatocytes and primary cell cultures. The kinetics of [3H]-bumetanide uptake revealed two saturable components in addition to an unsaturable component.
E. Petzinger +4 more
core +1 more source